Administrative Detention of Drugs Intended for Human or Animal Use; Correction, 22403 [2015-09301]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 77 / Wednesday, April 22, 2015 / Rules and Regulations
authority and/or Regulation Reserve
Sharing Group. These costs represent an
estimate of the costs a small entity could
incur if the entity is identified as an
applicable entity. The Commission does
not consider the estimated cost per
small entity to have a significant
economic impact on a substantial
number of small entities. The
Commission did not receive any
comments regarding this aspect of the
NOPR. Based on the above, the
Commission certifies that this Final
Rule will not have a significant
economic impact on a substantial
number of small entities. Accordingly,
no regulatory flexibility analysis is
required.
VIII. Document Availability
55. In addition to publishing the full
text of this document in the Federal
Register, the Commission provides all
interested persons an opportunity to
view and/or print the contents of this
document via the Internet through the
Commission’s Home Page (https://
www.ferc.gov) and in the Commission’s
Public Reference Room during normal
business hours (8:30 a.m. to 5:00 p.m.
Eastern time) at 888 First Street NE.,
Room 2A, Washington, DC 20426.
56. From the Commission’s Home
Page on the Internet, this information is
available on eLibrary. The full text of
this document is available on eLibrary
in PDF and Microsoft Word format for
viewing, printing, and/or downloading.
To access this document in eLibrary,
type the docket number excluding the
last three digits of this document in the
docket number field.
57. User assistance is available for
eLibrary and the Commission’s Web site
during normal business hours from the
Commission’s Online Support at (202)
502–6652 (toll free at 1–866–208–3676)
or email at ferconlinesupport@ferc.gov,
or the Public Reference Room at (202)
502–8371, TTY (202) 502–8659. Email
the Public Reference Room at
public.referenceroom@ferc.gov.
mstockstill on DSK4VPTVN1PROD with RULES
IX. Effective Date and Congressional
Notification
58. This Final Rule is effective June
22, 2015. The Commission has
determined, with the concurrence of the
Administrator of the Office of
Information and Regulatory Affairs of
OMB, that this rule is not a ‘‘major rule’’
as defined in section 351 of the Small
Business Regulatory Enforcement
Fairness Act of 1996.86 The Commission
will submit the final rule to both houses
86 See
5 U.S.C. 804(2).
VerDate Sep<11>2014
18:54 Apr 21, 2015
Jkt 235001
of Congress and to the General
Accountability Office.
By the Commission.
Issued: April 16, 2015.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
22403
paragraph is corrected to read: ‘‘We
certify that this final rule will not have
a significant economic impact on a
substantial number of small entities.’’
[FR Doc. 2015–09227 Filed 4–21–15; 8:45 am]
Dated: April 16, 2015.
Leslie Kux,
Associate Commissioner for Policy.
BILLING CODE 6717–01–P
[FR Doc. 2015–09301 Filed 4–21–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 1 and 16
[Docket ID ED–2014–OESE–0050]
Administrative Detention of Drugs
Intended for Human or Animal Use;
Correction
Food and Drug Administration,
HHS.
ACTION:
The Food and Drug
Administration (FDA) is correcting a
final rule entitled ‘‘Administrative
Detention of Drugs Intended for Human
or Animal Use’’ that appeared in the
Federal Register of May 29, 2014 (79 FR
30716). The rule sets forth the
procedures for detention of drugs
believed to be adulterated or
misbranded and amends the scope of
FDA’s part 16 regulatory hearing
procedures to include the
administrative detention of drugs. The
rule published with incorrect statements
regarding the impact of the final rule on
small entities. This document corrects
those errors.
DATES: Effective April 22, 2015 and
applicable beginning June 30, 2014.
FOR FURTHER INFORMATION CONTACT:
Emily Leongini, Office of Regulatory
Affairs, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 32,
Rm. 4339, Silver Spring, MD 20993–
0002, 301–796–5300,
FDASIAImplementationORA@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of May 29, 2014, in FR
Doc. 2014–12458, the following
corrections are made:
1. On page 30718, in the third
column, under ‘‘Analysis of Impacts
(Summary of the Regulatory Impact
Analysis),’’ the last sentence of the
second paragraph is corrected to read:
‘‘FDA certifies that this final rule will
not have a significant economic impact
on a substantial number of small
entities.’’
2. On page 30719, in the first column,
the third sentence of the last full
PO 00000
Frm 00047
Fmt 4700
Sfmt 4700
Indian Education Discretionary Grants
Program; Professional Development
Program and Demonstration Grants for
Indian Children Program
Office of Elementary and
Secondary Education, Department of
Education.
ACTION: Final regulations.
AGENCY:
Final rule; correction.
SUMMARY:
34 CFR Part 263
RIN 1810–AB19
[Docket No. FDA–2013–N–0365]
AGENCY:
DEPARTMENT OF EDUCATION
The Secretary amends the
regulations that govern the Professional
Development program and the
Demonstration Grants for Indian
Children program (Demonstration
Grants program), authorized under title
VII of the Elementary and Secondary
Act of 1965, as amended (ESEA). The
regulations govern the grant application
process for new awards for each
program for the next fiscal year in
which competitions are conducted for
that program and subsequent years. For
the Professional Development program,
the regulations enhance the project
design and quality of services to meet
the objectives of the program; establish
post-award requirements; and govern
the payback process for grants in
existence on the date these regulations
become effective. For the Demonstration
Grants program, the regulations add
new priorities, including a priority for
native youth community projects
(NYCPs), and new application
requirements.
SUMMARY:
These regulations are effective
May 22, 2015.
FOR FURTHER INFORMATION CONTACT: John
Cheek, U.S. Department of Education,
400 Maryland Avenue SW., Room
3W207, Washington, DC 20202–6135.
Telephone: (202) 401–0274 or by email:
john.cheek@ed.gov.
If you use a telecommunications
device for the deaf (TDD) or a text
telephone (TTY), call the Federal Relay
Service (FRS), toll free, at 1–800–877–
8339.
DATES:
E:\FR\FM\22APR1.SGM
22APR1
]]>Agencies
[Federal Register Volume 80, Number 77 (Wednesday, April 22, 2015)]
[Rules and Regulations]
[Page 22403]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-09301]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 1 and 16
[Docket No. FDA-2013-N-0365]
Administrative Detention of Drugs Intended for Human or Animal
Use; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a final
rule entitled ``Administrative Detention of Drugs Intended for Human or
Animal Use'' that appeared in the Federal Register of May 29, 2014 (79
FR 30716). The rule sets forth the procedures for detention of drugs
believed to be adulterated or misbranded and amends the scope of FDA's
part 16 regulatory hearing procedures to include the administrative
detention of drugs. The rule published with incorrect statements
regarding the impact of the final rule on small entities. This document
corrects those errors.
DATES: Effective April 22, 2015 and applicable beginning June 30, 2014.
FOR FURTHER INFORMATION CONTACT: Emily Leongini, Office of Regulatory
Affairs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
32, Rm. 4339, Silver Spring, MD 20993-0002, 301-796-5300,
FDASIAImplementationORA@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the Federal Register of May 29, 2014, in
FR Doc. 2014-12458, the following corrections are made:
1. On page 30718, in the third column, under ``Analysis of Impacts
(Summary of the Regulatory Impact Analysis),'' the last sentence of the
second paragraph is corrected to read: ``FDA certifies that this final
rule will not have a significant economic impact on a substantial
number of small entities.''
2. On page 30719, in the first column, the third sentence of the
last full paragraph is corrected to read: ``We certify that this final
rule will not have a significant economic impact on a substantial
number of small entities.''
Dated: April 16, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-09301 Filed 4-21-15; 8:45 am]
BILLING CODE 4164-01-P
